This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-06-2430v1 67/1/246    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Srinivasan, S. Articles by Chendil, D. Search for Related Content PubMed PubMed Citation Articles by Srinivasan, S. Articles by Chendil, D.

Par-4-Dependent Apoptosis by the Dietary Compound Withaferin A in Prostate Cancer Cells

Departments of ¹ Clinical Sciences, College of Health Sciences and ² Radiation Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky

Requests for reprints: Damodaran Chendil, Department of Clinical Sciences, College of Health Sciences, University of Kentucky, Room 124 E, 900 South Limestone Street, Lexington, KY 40536-0200. Phone: 859-323-1100, ext. 80851/80879; Fax: 859-257-2454; E-mail: dchen2{at}uky.edu.

Deletion or mutation of the androgen receptor (AR) renders prostate tumors refractory to apoptosis by androgen ablation, the mainstay of prostate cancer therapy. To identify novel therapeutics that can induce apoptosis regardless of the AR status of prostate cancer cells, we screened dietary herbal compounds using a reporter assay for the prostate apoptosis response-4 (Par-4) gene, which induces p53- and PTEN-independent and cancer-selective apoptosis. One of the compounds, withaferin A (WA), a major constituent of the dietary compound Withania somnifera, induced Par-4-dependent apoptosis in androgen-refractory prostate cancer cells and regression of PC-3 xenografts in nude mice. Interestingly, restoration of wild-type AR in PC-3 (AR negative) cells abrogated both Par-4 induction and apoptosis by WA. Individually, WA and anti-androgens induced neither Par-4 nor apoptosis in androgen-responsive prostate cancer cells, yet in combination, WA and anti-androgen synergistically induced Par-4 and apoptosis in androgen-responsive prostate cancer cells. Thus, when judiciously combined with anti-androgens, WA inhibits survival of both androgen-responsive and androgen-refractory prostate cancer cells by a Par-4-dependent mechanism. As Par-4 up-regulation induces apoptosis in most tumor cells, our findings can be extended to high-throughput screens to identify synergistic combinations for both therapy-sensitive and therapy-resistant cancers. [Cancer Res 2007;67(1):246–53]

This article has been cited by other articles:

				L. Ye, H. Kynaston, and W. G. Jiang Bone Morphogenetic Protein-9 Induces Apoptosis in Prostate Cancer Cells, the Role of Prostate Apoptosis Response-4 Mol. Cancer Res., October 1, 2008; 6(10): 1594 - 1606. [Abstract] [Full Text] [PDF]

				S. D. Stan, E.-R. Hahm, R. Warin, and S. V. Singh Withaferin A Causes FOXO3a- and Bim-Dependent Apoptosis and Inhibits Growth of Human Breast Cancer Cells In vivo Cancer Res., September 15, 2008; 68(18): 7661 - 7669. [Abstract] [Full Text] [PDF]